|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8074 USD | -13.18% |
|
-54.25% | -97.03% |
| Apr. 19 | Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product | MT |
| Apr. 19 | Top Premarket Decliners | MT |
Sunshine Biopharma, Inc announced to purchase 100,000 shares of Series B Preferred Stock for gross proceeds of $10,000 on March 4, 2024. The transaction included participation from Chief Executive Officer and Chairman, Dr. Steve Slilaty. Each share of the Preferred Stock is entitled to 1,000 votes per share.
The Series B Preferred Stock is non-convertible, non-redeemable, non-retractable, and has superior liquidation rights to the common stock at $0.10 per share.
| 1st Jan change | Capi. | |
|---|---|---|
| -97.03% | 945K | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
SUNSHINE BIOPHARMA, INC. 
